Related Experiment Video

Updated: Mar 17, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Plasma EMMPRIN levels in acute myocardial infarction and stable coronary artery disease

Mehmet N Akkus1, Adil Ormam, Sabri Seyis

  • 1. mnecdetakkus@hotmail.com.

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|July 22, 2016
PubMed

Insights

Plasma levels of extracellular matrix metalloproteinase inducer (EMMPRIN) were significantly higher in patients with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) compared to stable coronary artery disease (CAD) patients and healthy controls.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Molecular Biology

Background:

  • Extracellular matrix metalloproteinase inducer (EMMPRIN) is a key regulator of extracellular matrix remodeling.
  • Elevated EMMPRIN levels have been implicated in various cardiovascular diseases.
  • Understanding EMMPRIN's role in acute myocardial infarction (AMI) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate plasma EMMPRIN levels in ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), stable coronary artery disease (CAD), and healthy controls.
  • To identify factors associated with differential EMMPRIN expression in these patient groups.

Main Methods:

  • Plasma EMMPRIN levels were measured in four age- and sex-matched groups: STEMI, NSTEMI, stable CAD, and healthy controls (n=44 per group).
  • Logistic regression and correlation analyses were performed on the entire acute myocardial infarction (AMI) patient cohort.

Main Results:

  • EMMPRIN levels were significantly elevated in STEMI (39.4±9.2 ng/mL) and NSTEMI (37.1±10.5 ng/mL) groups compared to stable CAD (27.5±4.7 ng/mL) and control (24.5±5.8 ng/mL) groups.
  • Statistical significance was observed when comparing acute myocardial infarction groups with stable CAD and control groups (p < 0.05).

Conclusions:

  • Plasma EMMPRIN levels are significantly higher in patients experiencing acute myocardial infarction (STEMI and NSTEMI) than in those with stable CAD or in healthy individuals.
  • EMMPRIN may serve as a potential biomarker for acute myocardial infarction.
  • Further research is warranted to explore the clinical utility of EMMPRIN in cardiovascular disease management.
Abstract

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.4K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
384
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
637
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
710
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
405